Around half of people diagnosed with pancreatic cancer will have been diagnosed with diabetes recently, according to NHS ...

Roche's Hemlibra treatment for haemophilia A is one of its top-selling drugs, making almost $5 billion last year, and the ...

A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control ...

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

In early 2025, the White House renewed its push to lower prescription drug prices, part of an executive order aimed at easing patients' financial burdens. While the directive garnered headlines, many ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...

Originally employed in atomic physics, mass spectrometry is now an indispensable tool in modern science, and importantly ...

EY's latest Biotech Beyond Borders report acknowledges the seismic changes in the US in the last few months, including cuts ...

Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a treatment for metabolic ...

Gilead is now waiting for regulatory decisions on the twice-yearly PrEP in Europe and other markets, including South Africa ...

After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more ...